Print   

Wednesday 13 January, 2010

Skyepharma PLC

Holding(s) in Company

RNS Number : 5208F
Skyepharma PLC
13 January 2010
 






TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES


1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached:

  SkyePharma Plc


2 Reason for the notification (please tick the appropriate box or boxes):


An acquisition or disposal of voting rights

 


An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached

 


An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments

 


An event changing the breakdown of voting rights

 


Other (please specify):

  Delta adjustment

 X


3. Full name of person(s) subject to the notification obligation:


D.E. Shaw & Co., L.P.
D.E. Shaw & Co. (U.K.), Ltd.

4. Full name of shareholder(s) (if different from 3.):


 N/A

5. Date of the transaction and date on which the threshold is crossed or reached:


 January 11, 2010

6. Date on which issuer notified:


 January 13, 2010

7. Threshold(s) that is/are crossed or reached:


 32%

  

8. Notified details:

A: Voting rights attached to shares


Class/type of
shares


if possible using
the ISIN CODE

Situation previous
to the 
triggering
transaction

Resulting situation after the triggering transaction

Number
of

Shares

Number
of

V
oting
Rights

Number
of shares

Number of voting
rights

% of voting rights

Direct

Direct

Indirect

Direct

Indirect

 

 

 

 

 

 

 

 

 


B: Qualifying Financial Instruments

Resulting situation after the triggering transaction


Type of financial
instrument

Expiration
date

Exercise/ 
Conversion 
Period

Number of voting
rights that may be

acquired if the

instrument is

exercised/ converted.


% of voting
rights

 

 

 

 

 


C: Financial Instruments with similar economic effect to Qualifying Financial Instruments
Resulting situation after the triggering transaction
 
Type of financial
instrument
Exercise
price
Expiration
date
Exercise/
Conversion
period
Number of voting
rights instrument
refers to
% of voting rights
 
Contract for Differences ("CfD") relating to convertible bond due 2024
 
March 4, 2010
 
3,461,725
Nominal
Delta 
 
14.46%
CfD relating to convertible bond due 2025
 
December 3, 2010
 
2,058,916
Nominal
Delta
 
8.60%
CfD relating to convertible bond due 2025
 
June 3, 2010
 
 2,058,916
Nominal
Delta
 
 8.60%

 

 

Total (A+B+C)


Number of voting rights

Percentage of voting rights

 

7,579,557

 

31.66%


9. Chain of controlled undertakings through which the voting rights and/or the
financial instruments are effectively held, if applicable:

 

Each of D.E. Shaw & Co., L.P. ("DESCO LP") and D.E. Shaw & Co. (U.K.), Ltd. ("DESCO UK") is notifying solely in its capacity as a discretionary investment manager. As general partner of DESCO LP, D.E. Shaw & Co., Inc. ("DESCO Inc.") is a parent undertaking of DESCO LP and DESCO UK. By virtue of David E. Shaw's position as president and sole shareholder of DESCO, Inc., which is the general partner of DESCO LP, David E. Shaw is a parent undertaking of DESCO LP and DESCO UK.


Proxy Voting:


10. Name of the proxy holder:


 

11. Number of voting rights proxy holder will cease to hold:


 

12. Date on which proxy holder will cease to hold voting rights:


 


13. Additional information:


 

14. Contact name:


Stephen Back (Compliance Department)

15. Contact telephone number:


+1 212-478-0000 



This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
HOLDXLFFBFFLBBD

Investegate takes no responsibility for the accuracy of the information within the site.


The announcements are supplied by the denoted source. Queries about the content of an announcement should be directed to the source. Investegate reserves the right to publish a filtered set of announcements. NAV, EMM/EPT, Rule 8 and FRN Variable Rate Fix announcements are filitered from this site.



Investegate      © 2012 FE. All rights reserved.